Outcome of Treating Bladder Cancer in Sohag University Hospital

Retrospective study of outcome of urinary bladder cancer treated in Sohag University hospital in the past 5 years from 2016 to 2020

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bladder Cancer Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Neoplasms Neoplasms by Site Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag University Hospital

Sohag, Egypt

About this study

This study asses the risk factors, prognosis,disease free survival and overall survive rate of treating urinary badder cancer

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

all stages and grades of urinary bladder cancer Any histological types of urinary bladder cancer

Exclusion criteria

presence of other malignancies

Treatment and study plan

Chemotherapy, Radiotherapy and surgery

Combination Product

Trans urethral resection of the tumour or radical cystectomy

Primary outcomes

Disease free survival

Time frame: 2 weeks after treatment to the time of relapse

Time from the end of treatment to the date of first relapse

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Outcome of Treating Urinary Bladder Cancer in Sohag University Hospital Between 2016 to 2020

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Oct 19, 2021
Registry last updated: Jun 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed